Savara secures accelerated review in the UK for autoimmune PAP therapy MOLBREEVI
Savara (NASDAQ:SVRA), a clinical-stage biopharmaceutical company dedicated to rare respiratory diseases, announced on April 7, 2026, that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted its Marketing Authorisation Application (MAA) for MOLBREEVI.








-640x360.webp&w=3840&q=75)


